Influence of cellular ganglioside depletion on tumor formation

Journal of the National Cancer Institute

Volumn 92, Issue 11, 2000, Pages 912-917

  Deng, Wen ^b   Li, Ruixiang ^b   Ladisch, Stephan ^a  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GANGLIOSIDE; PROPANOL; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DEPLETION; FEMALE; LUNG METASTASIS; MELANOMA B16; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

EID: 0034616635     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.11.912     Document Type: Article

References (41)

1. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
2. Young WW Jr, Borgman CA, Wolock DM. Modes of shedding of glycosphingolipids from mouse lymphoma cells. J Biol Chem 1986;261: 2279-83.
3. Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983;43: 3808-13.
4. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987;39:73-6.
5. Chang F, Li R, Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res 1997;234:341-6.
6. Stallcup WB. Involvement of gangliosides and glycoprotein fibronectin receptors in cellular adhesion to fibronectin. Exp Cell Res 1988;177: 90-102.
7. Satoh M, Handa K, Saito S, Tokuyama S, Ito A, Miyao N, et al. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res 1996;56: 1932-8.
8. De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, et al. Requirement for GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science 1997;277:1652-5.
9. Kopitz J, von Reitenstein C, Burchert M, Cantz M, Gabius HJ. Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J Biol Chem 1998;273:11205-11.
10. Iwabuchi K, Yamamura S, Prinetti A, Handa K, Hakomori S. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells. J Biol Chem 1998;273:9130-8.
11. Gonwa TA, Westrick MA, Macher BA. Inhibition of mitogen-and antigen-induced lymphocyte activation by human leukemia cell gangliosides. Cancer Res 1984;44:3467-70.
12. Robb RJ. The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association. J Immunol 1986;136:971-6.
13. Chu JW, Sharom FJ. Gangliosides interact with interleukin-4 and inhibit interleukin-4-siimulated helper T-cell proliferation. Immunology 1995;84: 396-403.
14. Bergelson LD. Dyatlovitskaya EV, Klyuehareva TE, Kryukova EV, Lemenovskaya AF, Matveeva VA, et al. The role of glycosphingolipids in natural immunity. Gangliosides modulate the cytotoxicity of natural killer cells. Eur J Immunol 1989;9:1979-83.
15. Zhou J, Shao H, Cox NR, Baker HJ, Ewald SJ. Gangliosides enhance apoptosis of thymocytes. Cell Immunol 1998;183:90-8.
16. Yogeeswaran G, Mbawuike IN. Altered metabolism and cell surface expression of glycosphingolipids caused by vitamin E in cultured murine (K3T3) reticulum sarcoma cells. Lipids 1986;21:643-7.
17. Ladisch S, Kitada S, Hays EF. Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 1987;79:1879-82.
18. Tsuchida T, Saxton RE, Irie RF. Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst 1987;78:55-60.
19. Albino AP, Sozzi G. Nanus DM, Jhanwar SC, Houghton AN. Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene 1992;7:2315-21.
20. Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y. A mouse B16 melanoma mutant deficient in glycolipids. Proc Natl Acad Sci U S A 1994;91: 2703-7.
21. Ladisch S, Becker H, Ulsh L. Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim Biophys Acta 1992;1125:180-8.
22. Ledeen RW, Yu RK. Gangliosides: structures, isolation, and analysis. Methods Enzymol 1982;83:139-91.
23. Ladisch S, Sweeley CC, Becker H, Gage D. Aberrant fatty acyl alpha-hydroxylation in human neuroblastoma tumor gangliosides. J Biol Chem 1989;264:12097-105.
24. Inokuchi J, Jimbo M, Momosaki K, Shimeno H, Nagamatsu A, Radin NS. Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res 1990;50:6731-7.
25. Rani CS, Abe A. Chang Y, Rosenzweig N, Saltiel AR, Radin NS, et al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem 1995;270:2859-67.
26. Tokuyama S, Moriya S, Taniguchi S, Yasui A, Miyazaki J, Orikasa S, et al. Suppression of pulmonary metastasis in murine B16 melanoma cells by transfection of a sialidase cDNA. Int J Cancer 1997;73:410-5.
27. Skipski VP, Carter SP, Terebus-Kekish OI, Podlaski FJ Jr, Peterson RH, Stock CC. Ganglioside profiles of metastases and of metastasizing and nonmetastasizing rat primary mammary carcinomas. J Natl Cancer Inst 1981;67:1251-8.
28. Nozue M, Sakiyama H, Tsuchiya K, Hirabayashi Y, Taniguchi M. Melanoma antigen expression and metastatic ability of mutant B16 melanoma clones. Int J Cancer 1988;42:734-8.
29. Taki T, Ishikawa D, Ogura M, Nakajima M, Handa S. Ganglioside GD1alpha functions in the adhesion of metastatic tumor cells to endothelial cells of the target tissue. Cancer Res 1997;57:1882-8.
30. Radin NS. Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol 1994;21: 111-27.
31. Li R, Ladisch S. Abrogation of shedding of immunosuppressive neuroblastoma gangliosides. Cancer Res 1996;56:4602-5.
32. Kyogashima M, Inoue M, Seto A, Inokuchi J. Glucosylceramide synthetase inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol exhibits a novel decarcinogenic activity against Shope carcinoma cells. Cancer Lett 1996;101:25-30.
33. Barbour S. Edidin M, Felding-Habermann B, Taylor-Norton J, Radin NS, Fenderson BA. Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells. J Cell Physiol 1992;150:610-9.
34. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R, et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 1995;36:611-21.
35. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J Biol Chem 1999;274:14662-9.
36. Nicholson KM, Quinn DM, Kellett GL, Warr JR. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer 1999;81;423-30.
37. Olshefski RS. Ladisch S. Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: abrogation by a new inhibitor of glucosylceramide synthase. J Neurochem 1998;70;467-72.
38. Chu JW, Sharom FJ. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 1993;79:10-7.
39. Li R, Villacreses N, Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995;55:211-4.
40. Heitger A, Ladisch S. Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta 1996;1303:161-8.
41. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999;163:3718-26.